ATO-101 (211At-labeled girentuximab)
/ ATONCO, Telix
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 18, 2026
A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU)
(clinicaltrialsregister.eu)
- P1 | N=24 | Not yet recruiting | Sponsor: Institut De Cancerologie De L Ouest
First-in-human • New P1 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
December 04, 2025
Evaluation of Safety, Tolerability and Response of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Institut Cancerologie de l'Ouest
First-in-human • New P1 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1